Neoadjuvant FOLFIRINOX Application in Borderline Resectable Pancreatic Adenocarcinoma: A Retrospective Cohort Study

5-Fluorouracile, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) has not been extensively used in the neoadjuvant setting because of concerns with safety and toxicity. We evaluated our institutional experience with neoadjuvant FOLFIRINOX in borderline resectable pancreatic adenocarcinoma (BRPAC...

Descripción completa

Detalles Bibliográficos
Autores principales: Paniccia, Alessandro, Edil, Barish H., Schulick, Richard D., Byers, Joshua T., Meguid, Cheryl, Gajdos, Csaba, McCarter, Martin D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2014
Materias:
7100
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602784/
https://www.ncbi.nlm.nih.gov/pubmed/25501072
http://dx.doi.org/10.1097/MD.0000000000000198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602784/
https://www.ncbi.nlm.nih.gov/pubmed/25501072
http://dx.doi.org/10.1097/MD.0000000000000198

Ejemplares similares